Evidence map›Paper›PMID 31658936›Full record

ReviewDeutsches Arzteblatt international2019

The Role of Microbiota in Preventing Multidrug-Resistant Bacterial Infections.

Yascha Khodamoradi, Johanna Kessel, Jörg Janne Vehreschild, Maria J G T Vehreschild

Abstract readReview
In one paragraph

Review in Deutsches Arzteblatt international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Microbial genomics · 2026
    Article
  2. Review
  3. JAC-antimicrobial resistance · 2025
    Article
  4. [Precision medicine in infectious diseases].Innere Medizin (Heidelberg, Germany) · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yascha KhodamoradiDepartment of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Johann Wolfgang Goethe University, Frankfurt am Main; Department of Internal Medicine, Hematology/Oncology, University Hospital Frankfurt, Johann Wolfgang Goethe University, Frankfurt am Main; Department I of Internal Medicine, University Hospital of Cologne, Center for Integrated Oncology Aachen, Bonn, Köln, Düsseldorf; German Center for Infection Research (DZIF), Bonn-Cologne.
Johanna Kessel
Jörg Janne Vehreschild
Maria J G T Vehreschild

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe introduction of industrially produced antibiotics was a milestone in the history of medicine. Now, almost a century later, the adverse consequences of these highly effective drugs have become evident in the form of antibiotic-resistant infections, which are on the rise around the world. The search for solutions to this problem has involved both the introduction of newer types of antibiotics and, increasingly, the development of alternative strategies to prevent infections due to multidrug-resistant bacteria. In this article, we review the pathophysiological connection between the use of antibiotics and the occurrence of such infections. We also discuss some alternative strategies that are currently under development.

methodsThis review is based on pertinent articles that appeared from January 2000 to April 2019 and were retrieved by a selective search in the PubMed database employing the search term "(microbiota OR microbiome) AND infection." Further suggestions by our author team regarding relevant literature were considered as well.

resultsThe spectrum of preventive strategies encompasses measures for the protection of the intestinal microbiota (antimicrobial stewardship, neutralization of antibiotic residues in the bowel, use of phages and species-specific antibiotics) as well as measures for its reconstitution (prebiotics, probiotics, and fecal microbiota transfer).

conclusionIn view of the major problem that multidrug-resistant bacteria pose for the world's population and the resources now being spent on the search for a solution, derived both from public funding and from the pharmaceutical industry, we hope to see new, clinically useful approaches being developed and implemented in the near future.

Indexed as

Drug Resistance, Multiple, BacterialAnti-Bacterial AgentsBacterial InfectionsHumansMicrobiotaAnti-Bacterial Agents

Identifiers

PMID31658936
PMCPMC6859878

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.